新一代抗体偶联小分子药物(ADC)
ADC has emerged as an important modality to deliver drugs with improved precision, and will remain an important modality against cancer. InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing. We firmly believe that we can develop ADCs for tumor selective across with relatively broad spectrum but also relatively normal tissue sparing.
Our next generation ADCs will be entering IND enabling study in Q3 2024 and will address the key unmet medical need.

我们致力于开发针对肿瘤耐药和转移的创新疗法
快速链接
联系我们
电话: 025-58251030
邮箱: office@inxmed.com
公司地址: 南京市江北新区探秘路73号树屋十六栋D-2栋3层
在线留言
关注我们:
CopyRight © 2022 应世生物 All Rights Reserved.